Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Apax Partner’s portfolio company Destiny in connection with its acquisition of Soluno
Mandate

Vinge advises Apax Partner’s portfolio company Destiny in connection with its acquisition of Soluno

June 21, 2021 Employment and Benefits Commercial Agreements M&A IT, Telecommunications and Outsourcing Real Estate and Construction Corporate Crime & Compliance Intellectual Property

Vinge advises Destiny (a portfolio company of Apax Partners) in connection with its acquisition of the Soluno group (“Soluno”).

Soluno is one of the leading unified communications as a service providers in Europe. The acquisition gives Destiny an instantly strong position in Sweden and also leads to globalisation for Soluno. Following the acquisition, Destiny will comprise of more than 600 employees across 6 countries and is expected to generate a turnover of SEK 1.7 billion in 2021.

Vinge’s team mainly consisted of Christina Kokko, Ulrich Ziche, Hannah Kajlinger and Carl Fredrik Wachtmeister (M&A), Lisa Hörnqvist (Commercial Agreements and GDPR), Mathilda Persson (IT), Ulf Pyk (Real Estate), Josefine Lanker (Banking and Financing), Ebba Svenburg (Employment), Tove Lövgren Frisk (Compliance), Felizia Wiker (IP) and Sara Dahlroos Sköld (VDR specialist).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026